Belgium· BE-AMP-SAM660602-00
Scemblix 40 mg
A asciminib product containing asciminib hydrochloride, registered in Belgium by Novartis Europharm. The same ATC class is registered in 16 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Asciminib is registered in 16 of 19 countries.
Countries holding a registration under ATC L01EA06 (asciminib), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 10 of them publish a price we can compare per daily dose
Asciminib · ATC L01EA06
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of asciminib costs, country by country.
Normalised to the WHO defined daily dose (80 mg), the median price runs from $0.27 in France to $162.23 in Switzerland — a ×606 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Asciminib · price per daily dose (80 mg)
USD · FX 28 Sept 2026
- CH Switzerland$162.23
- FR France$0.27
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Asciminib Hydrochloride
- Manufacturer
- Novartis Europharm
- Country
- Belgium (BE)
- ATC code
- L01EA06
- ATC class
- Asciminib
- Defined daily dose
- 80 mg, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb4624672
- be_apb7737620
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Asciminib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSCEMBLIXNovartis Europharm Limited, Dublin
- SpainSCEMBLIX 40 MG COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- FinlandScemblixNovartis Europharm Limited
- FranceSCEMBLIX 40 mg, comprimés pelliculésNOVARTIS EUROPHARM (IRLANDE)
- IrelandScemblix 40 mg film-coated tabletsNovartis Europharm Limited
- IcelandScemblixNovartis Europharm Limited*
- NetherlandsScemblix 40mg, filmomhulde tabletNovartis Europharm Limited
- NorwayScemblixNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Scemblix
- Liechtenstein · Scemblix
- Norway · Scemblix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ba62d761-b192-40a1-b860-18ff5cc93788 GET /v1/drugs/ba62d761-b192-40a1-b860-18ff5cc93788?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Scemblix 40 mg",
"name_fr": "Scemblix 40 mg",
"name_nl": "Scemblix 40 mg",
"amp_code": "SAM660602-00",
"strengths": [
"43.2400",
"43.2400",
"43.2400",
"43.2400",
"40.0000",
"40.0000",
"40.0000",
"40.0000",
"86.0000"
],
"pack_count": 3,
"substances": [
"Asciminib Hydrochloride",
"Asciminib",
"Lactose Monohydrate"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Asciminib",
"authorisation_numbers": [
"EU/1/22/1670/003",
"EU/1/22/1670/004",
"EU/1/22/1670/005"
]
}See everything about asciminib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.